| dc.contributor.author | Cetin, Idil | |
| dc.contributor.author | Topcul, Mehmet | |
| dc.date.accessioned | 2021-03-03T17:36:16Z | |
| dc.date.available | 2021-03-03T17:36:16Z | |
| dc.date.issued | 2014 | |
| dc.identifier.citation | Cetin I., Topcul M., "Triple Negative Breast Cancer", ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.6, ss.2427-2431, 2014 | |
| dc.identifier.issn | 1513-7368 | |
| dc.identifier.other | av_4a833216-3b84-4852-bc94-00af279c3645 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/53537 | |
| dc.identifier.uri | https://doi.org/10.7314/apjcp.2014.15.6.2427 | |
| dc.description.abstract | Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients. | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Onkoloji | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Triple Negative Breast Cancer | |
| dc.type | Makale | |
| dc.relation.journal | ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | |
| dc.contributor.department | İstanbul Üniversitesi , Fen Fakültesi , Biyoloji Bölümü | |
| dc.identifier.volume | 15 | |
| dc.identifier.issue | 6 | |
| dc.identifier.startpage | 2427 | |
| dc.identifier.endpage | 2431 | |
| dc.contributor.firstauthorID | 59631 | |
